Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement: A randomised, controlled trial

Thrombosis and Haemostasis

Volumn 109, Issue 6, 2013, Pages 1091-1098

  Verhamme, Peter ^a,b   Gunn, Sophie ^c   Sonesson, Elisabeth ^d   Peerlinck, Kathelijne ^a,b   Vanassche, Thomas ^a,b   Vandenbriele, Christophe ^a,b   Ageno, Walter ^e   Glazer, Steven ^d   Prins, Martin ^f   Buller, Harry ^g   Tangelder, Marco ^c,h  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c Clinical Department   (Belgium)

^d AstraZeneca RandD   (Sweden)

^e UNIVERSITY OF INSUBRIA   (Italy)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g ACADEMIC MEDICAL CENTER   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Deep vein thrombosis; Factor VIII; Rivaroxaban; TB 402; Thrombo prophylaxis; Total hip replacement; Venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 8; MONOCLONAL ANTIBODY; PLACEBO; RIVAROXABAN; TB 402; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ARTICLE; BLEEDING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HEMORRHOID HEMORRHAGE; HUMAN; HYPERTENSION; LUNG ANGIOGRAPHY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PHLEBOGRAPHY; PLASMA HALF LIFE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH ULCER; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL HIP PROSTHESIS; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, INTRAVENOUS; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MORPHOLINES; PATIENT SAFETY; POSTOPERATIVE COMPLICATIONS; RISK; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84878632006     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-01-0066     Document Type: Article

References (17)

1. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembol-ism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (6 Suppl): 381S-453S.
2. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010; 121: 1523-1532.
3. Emmerechts J, Vanassche T, Loyen S, et al. Partial versus complete factor VIII inhibition in a mouse model of venous thrombosis. Thromb Res 2012; 129: 514-519.
4. Jacquemin M, Radcliffe CM, Lavend'homme R, et al. Variable region heavy chain glycosylation determines the anticoagulant activity of a factor VIII antibody. J Thromb Haemost 2006; 4: 1047-1055.
5. Jacquemin M, Stassen JM, Saint-Remy JM, et al. A human monoclonal antibody inhibiting partially factor VIII activity reduces thrombus growth in baboons. J Thromb Haemost 2009; 7: 429-437.
6. Verhamme P, Pakola S, Jensen TJ, et al. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther 2010; 32: 1205-1220.
7. Verhamme P, Tangelder M, Verhaeghe R, et al. Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial. J Thromb Haemost 2011; 9: 664-671.
8. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008; 358: 2765-2775.
9. Tangelder M, Long C, Emmerechts J, et al. Antidote strategies to reverse antico-agulation with TB-402, a long-acting partial inhibitor of factor VIII. J Thromb Haemost 2012; 10: 1371-1378.
10. Buller HR, Cohen AT, Davidson B, et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med 2007; 357: 1094-1104.
11. Schulman S, Angeras U, Bergqvist D, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 2010; 8: 202-204.
12. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
13. Newcombe RG. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998; 17: 873-890.
14. Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous throm-boembolism in patients undergoing elective hip or knee surgery. J Thromb Hae-most 2007; 5: 1438-1443.
15. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008; 358: 2776-2786.
16. Strebel N, Prins M, Agnelli G, et al. Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med 2002; 162: 1451-1456.
17. Singh I, Smith A, Vanzieleghem B, et al. Antithrombotic effects of controlled inhibition of factor VIII with a partially inhibitory human monoclonal antibody in a murine vena cava thrombosis model. Blood 2002; 99: 3235-3240.